Genomma Lab may raise debt to produce vaccines

Genomma Lab may raise debt to produce vaccines

Debt Funds Latin America South America Argentina Brazil Chile Colombia Costa Rica Mexico Capital Markets ESG Commerce Healthcare Coronavirus

Mexico's Genomma Lab International may have to raise debt to produce enough COVID-19 vaccines to meet demand in Latin America following the creation of a joint venture with Israel's Oramed Pharmaceuticals. "Possibly, once the vaccine is authorized and we have orders of a magnitude in the 10s of millions, we would need to raise some debt," Rodrigo Herrera, founder and chairman of Genomma Lab, told LatinFinance on Thursday. "That would be the least of all our problems, but we are not planning to r

Already have an account?

Free trial

Take a free two-week trial now for the latest news, data and market analysis.

Free Trial